Michael Kahn
Concepts (419)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta Catenin | 17 | 2024 | 253 | 4.410 |
Why?
| | Electronic Health Records | 22 | 2024 | 1046 | 2.620 |
Why?
| | Wnt Signaling Pathway | 12 | 2024 | 192 | 2.160 |
Why?
| | Medical Informatics | 6 | 2017 | 101 | 1.670 |
Why?
| | Data Accuracy | 7 | 2024 | 65 | 1.580 |
Why?
| | Neoplastic Stem Cells | 8 | 2021 | 399 | 1.530 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2024 | 121 | 1.440 |
Why?
| | Medical Record Linkage | 9 | 2024 | 64 | 1.390 |
Why?
| | Biomedical Research | 9 | 2018 | 688 | 1.360 |
Why?
| | p300-CBP Transcription Factors | 3 | 2018 | 26 | 1.240 |
Why?
| | CREB-Binding Protein | 4 | 2018 | 31 | 1.210 |
Why?
| | Pediatrics | 5 | 2019 | 1094 | 1.200 |
Why?
| | Catenins | 2 | 2018 | 6 | 1.120 |
Why?
| | Crowding | 3 | 2011 | 35 | 1.070 |
Why?
| | Health Services Research | 3 | 2019 | 400 | 0.930 |
Why?
| | Pyrimidinones | 7 | 2018 | 113 | 0.890 |
Why?
| | Computer Communication Networks | 2 | 2014 | 33 | 0.880 |
Why?
| | Comparative Effectiveness Research | 5 | 2017 | 150 | 0.870 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 8 | 2018 | 227 | 0.860 |
Why?
| | Quality of Health Care | 4 | 2013 | 634 | 0.790 |
Why?
| | Rare Diseases | 1 | 2023 | 101 | 0.780 |
Why?
| | Imatinib Mesylate | 2 | 2024 | 79 | 0.780 |
Why?
| | Data Warehousing | 1 | 2022 | 5 | 0.770 |
Why?
| | Cloud Computing | 1 | 2022 | 7 | 0.770 |
Why?
| | Glioma | 2 | 2024 | 395 | 0.720 |
Why?
| | Patient-Centered Care | 3 | 2014 | 522 | 0.670 |
Why?
| | Information Storage and Retrieval | 5 | 2020 | 117 | 0.650 |
Why?
| | Clinical Trials as Topic | 5 | 2017 | 1044 | 0.640 |
Why?
| | Quality Assurance, Health Care | 3 | 2012 | 322 | 0.620 |
Why?
| | Machine Learning | 2 | 2023 | 488 | 0.600 |
Why?
| | Genomic Instability | 1 | 2018 | 53 | 0.570 |
Why?
| | gamma Catenin | 1 | 2017 | 13 | 0.550 |
Why?
| | Urology | 1 | 2018 | 63 | 0.550 |
Why?
| | Heterocyclic Compounds, 2-Ring | 1 | 2017 | 12 | 0.540 |
Why?
| | Child Health | 1 | 2019 | 154 | 0.530 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 145 | 0.510 |
Why?
| | Humans | 80 | 2025 | 136803 | 0.510 |
Why?
| | Hematopoiesis | 1 | 2017 | 190 | 0.490 |
Why?
| | Radiation Injuries | 1 | 2017 | 145 | 0.490 |
Why?
| | Medical Records Systems, Computerized | 4 | 2012 | 92 | 0.490 |
Why?
| | Data Mining | 2 | 2017 | 116 | 0.490 |
Why?
| | Databases, Factual | 6 | 2019 | 1351 | 0.480 |
Why?
| | Child Welfare | 2 | 2014 | 212 | 0.470 |
Why?
| | Evolution, Molecular | 1 | 2018 | 488 | 0.440 |
Why?
| | Terminology as Topic | 2 | 2014 | 216 | 0.440 |
Why?
| | Forms and Records Control | 1 | 2013 | 23 | 0.430 |
Why?
| | Community Networks | 1 | 2014 | 57 | 0.420 |
Why?
| | Quality Indicators, Health Care | 3 | 2013 | 307 | 0.400 |
Why?
| | Quality Improvement | 1 | 2021 | 1163 | 0.400 |
Why?
| | Population Surveillance | 3 | 2020 | 474 | 0.380 |
Why?
| | Nursing Assessment | 1 | 2011 | 57 | 0.350 |
Why?
| | Analgesia | 1 | 2011 | 94 | 0.350 |
Why?
| | Embryonic Stem Cells | 1 | 2011 | 123 | 0.350 |
Why?
| | Antineoplastic Agents | 4 | 2021 | 2123 | 0.340 |
Why?
| | Wearable Electronic Devices | 2 | 2021 | 53 | 0.340 |
Why?
| | Cell Line, Tumor | 10 | 2024 | 3406 | 0.340 |
Why?
| | MicroRNAs | 4 | 2021 | 692 | 0.330 |
Why?
| | Emergency Service, Hospital | 2 | 2011 | 2048 | 0.320 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2010 | 77 | 0.320 |
Why?
| | Information Dissemination | 3 | 2019 | 215 | 0.320 |
Why?
| | Models, Statistical | 2 | 2019 | 668 | 0.320 |
Why?
| | Child | 17 | 2020 | 21819 | 0.310 |
Why?
| | Pain | 2 | 2011 | 755 | 0.310 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 223 | 0.300 |
Why?
| | Accidental Falls | 1 | 2011 | 193 | 0.290 |
Why?
| | United States | 18 | 2022 | 14691 | 0.290 |
Why?
| | Mice | 15 | 2024 | 17759 | 0.290 |
Why?
| | Luciferases | 2 | 2019 | 149 | 0.290 |
Why?
| | Mass Screening | 2 | 2020 | 1267 | 0.290 |
Why?
| | Heart Defects, Congenital | 3 | 2020 | 833 | 0.290 |
Why?
| | Animals | 20 | 2024 | 36850 | 0.280 |
Why?
| | Algorithms | 5 | 2024 | 1690 | 0.270 |
Why?
| | Organizational Policy | 1 | 2007 | 82 | 0.260 |
Why?
| | Pain Management | 2 | 2025 | 348 | 0.260 |
Why?
| | Pregnenes | 1 | 2006 | 1 | 0.260 |
Why?
| | Fluorine | 1 | 2006 | 16 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2020 | 2518 | 0.250 |
Why?
| | Cell Differentiation | 3 | 2024 | 1982 | 0.250 |
Why?
| | Pain Clinics | 1 | 2025 | 4 | 0.240 |
Why?
| | Pain, Postoperative | 2 | 2025 | 266 | 0.240 |
Why?
| | Emergency Medical Services | 1 | 2011 | 547 | 0.240 |
Why?
| | Transitional Care | 1 | 2025 | 40 | 0.230 |
Why?
| | Patient Care Team | 2 | 2025 | 626 | 0.230 |
Why?
| | Neoplasms | 2 | 2017 | 2643 | 0.230 |
Why?
| | Receptors, Glucocorticoid | 1 | 2006 | 155 | 0.220 |
Why?
| | Biological Science Disciplines | 1 | 2024 | 17 | 0.220 |
Why?
| | Knowledge Bases | 1 | 2024 | 27 | 0.220 |
Why?
| | Wnt Proteins | 3 | 2016 | 133 | 0.220 |
Why?
| | Adolescent | 16 | 2022 | 21385 | 0.220 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2020 | 3710 | 0.220 |
Why?
| | Analgesics, Opioid | 3 | 2025 | 993 | 0.210 |
Why?
| | Pattern Recognition, Automated | 1 | 2024 | 73 | 0.210 |
Why?
| | Child, Preschool | 9 | 2020 | 10997 | 0.210 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 50 | 0.210 |
Why?
| | Time Factors | 5 | 2025 | 6809 | 0.210 |
Why?
| | Phenotype | 3 | 2023 | 3189 | 0.200 |
Why?
| | Pyrazoles | 1 | 2006 | 423 | 0.200 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 672 | 0.190 |
Why?
| | Pyridines | 1 | 2006 | 506 | 0.190 |
Why?
| | Adrenal Cortex Hormones | 1 | 2006 | 556 | 0.190 |
Why?
| | Androgens | 1 | 2024 | 187 | 0.190 |
Why?
| | Data Collection | 3 | 2014 | 668 | 0.190 |
Why?
| | Precision Medicine | 2 | 2024 | 426 | 0.190 |
Why?
| | Mouth Neoplasms | 1 | 2023 | 120 | 0.190 |
Why?
| | Cell Movement | 4 | 2023 | 968 | 0.180 |
Why?
| | Infant | 7 | 2020 | 9395 | 0.180 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2022 | 164 | 0.180 |
Why?
| | Life Cycle Stages | 1 | 2021 | 41 | 0.180 |
Why?
| | Asthma | 3 | 2011 | 2282 | 0.180 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 288 | 0.180 |
Why?
| | Hyaluronan Receptors | 2 | 2018 | 103 | 0.180 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 621 | 0.170 |
Why?
| | MDS1 and EVI1 Complex Locus Protein | 1 | 2020 | 8 | 0.170 |
Why?
| | Education, Distance | 1 | 2021 | 48 | 0.170 |
Why?
| | Recurrence | 1 | 2024 | 1055 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2022 | 361 | 0.170 |
Why?
| | Tumor Stem Cell Assay | 2 | 2018 | 34 | 0.170 |
Why?
| | Molecular Targeted Therapy | 3 | 2021 | 411 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2021 | 800 | 0.160 |
Why?
| | Chromatin | 1 | 2024 | 519 | 0.160 |
Why?
| | India | 4 | 2020 | 193 | 0.160 |
Why?
| | Colorado | 8 | 2024 | 4515 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2022 | 248 | 0.160 |
Why?
| | Information Services | 1 | 2019 | 49 | 0.160 |
Why?
| | Information Management | 2 | 2012 | 18 | 0.160 |
Why?
| | Young Adult | 8 | 2020 | 13129 | 0.150 |
Why?
| | Immunotherapy | 1 | 2024 | 640 | 0.150 |
Why?
| | Sentinel Surveillance | 2 | 2018 | 48 | 0.150 |
Why?
| | Cell Proliferation | 5 | 2023 | 2476 | 0.150 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 595 | 0.150 |
Why?
| | Penicillin Resistance | 1 | 1998 | 8 | 0.150 |
Why?
| | Cell Cycle Proteins | 1 | 2023 | 613 | 0.150 |
Why?
| | Opioid-Related Disorders | 2 | 2025 | 509 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 279 | 0.150 |
Why?
| | Acute Disease | 2 | 2011 | 1007 | 0.150 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 224 | 0.150 |
Why?
| | Male | 17 | 2025 | 67330 | 0.150 |
Why?
| | Metabolic Syndrome | 1 | 2022 | 354 | 0.140 |
Why?
| | Adult | 12 | 2025 | 37643 | 0.140 |
Why?
| | Female | 18 | 2025 | 72816 | 0.140 |
Why?
| | Colorectal Neoplasms | 2 | 2020 | 791 | 0.140 |
Why?
| | Reproducibility of Results | 4 | 2021 | 3265 | 0.140 |
Why?
| | Toxicity Tests | 1 | 2018 | 37 | 0.140 |
Why?
| | Cisplatin | 2 | 2021 | 320 | 0.140 |
Why?
| | Liver Neoplasms | 2 | 2022 | 785 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1058 | 0.140 |
Why?
| | Infant, Newborn | 5 | 2020 | 6032 | 0.140 |
Why?
| | Pneumococcal Infections | 1 | 1998 | 115 | 0.140 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 64 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 647 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2017 | 119 | 0.140 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 200 | 0.140 |
Why?
| | Research Design | 4 | 2021 | 1127 | 0.140 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2017 | 128 | 0.130 |
Why?
| | Fractures, Bone | 2 | 2011 | 376 | 0.130 |
Why?
| | Pain Measurement | 2 | 2025 | 521 | 0.130 |
Why?
| | E1A-Associated p300 Protein | 1 | 2016 | 11 | 0.120 |
Why?
| | Hospitals, University | 2 | 2011 | 182 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2017 | 868 | 0.120 |
Why?
| | Cross Infection | 1 | 1998 | 250 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2011 | 5424 | 0.120 |
Why?
| | Vocabulary, Controlled | 2 | 2014 | 47 | 0.120 |
Why?
| | Adult Stem Cells | 1 | 2016 | 39 | 0.120 |
Why?
| | Logistic Models | 2 | 2011 | 2067 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 809 | 0.120 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 321 | 0.120 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 63 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 562 | 0.110 |
Why?
| | Antigens, CD | 1 | 2018 | 521 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 434 | 0.110 |
Why?
| | Protein Kinase C | 1 | 2016 | 261 | 0.110 |
Why?
| | Receptors, Notch | 1 | 2015 | 88 | 0.110 |
Why?
| | Program Development | 2 | 2019 | 364 | 0.110 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 505 | 0.110 |
Why?
| | Hydronephrosis | 1 | 2014 | 36 | 0.110 |
Why?
| | Renin-Angiotensin System | 1 | 2014 | 84 | 0.110 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2015 | 209 | 0.110 |
Why?
| | Database Management Systems | 2 | 2012 | 51 | 0.110 |
Why?
| | Hedgehog Proteins | 1 | 2015 | 195 | 0.110 |
Why?
| | Hematopoietic Stem Cells | 1 | 2017 | 402 | 0.110 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2015 | 176 | 0.110 |
Why?
| | Organizational Innovation | 1 | 2014 | 138 | 0.100 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1272 | 0.100 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 30 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2023 | 1396 | 0.100 |
Why?
| | Interinstitutional Relations | 1 | 2013 | 53 | 0.100 |
Why?
| | Chronic Disease | 1 | 2019 | 1786 | 0.100 |
Why?
| | Odds Ratio | 2 | 2011 | 1066 | 0.100 |
Why?
| | Patient Handoff | 1 | 2013 | 32 | 0.100 |
Why?
| | Patient Identification Systems | 1 | 2013 | 16 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 250 | 0.100 |
Why?
| | Signal Transduction | 4 | 2015 | 5077 | 0.100 |
Why?
| | Cell Line | 5 | 2019 | 2838 | 0.100 |
Why?
| | Models, Theoretical | 2 | 2017 | 575 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2018 | 4192 | 0.100 |
Why?
| | Postoperative Period | 1 | 2013 | 343 | 0.100 |
Why?
| | Retrospective Studies | 6 | 2022 | 15510 | 0.100 |
Why?
| | Multicenter Studies as Topic | 1 | 2013 | 308 | 0.090 |
Why?
| | Ethics Committees, Research | 1 | 2012 | 41 | 0.090 |
Why?
| | TCF Transcription Factors | 1 | 2011 | 17 | 0.090 |
Why?
| | Documentation | 1 | 2013 | 191 | 0.090 |
Why?
| | Registries | 4 | 2020 | 2015 | 0.090 |
Why?
| | Risk Assessment | 2 | 2011 | 3434 | 0.090 |
Why?
| | Mice, Transgenic | 1 | 2017 | 2163 | 0.090 |
Why?
| | Operating Rooms | 1 | 2013 | 123 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1033 | 0.090 |
Why?
| | Narcotics | 1 | 2011 | 52 | 0.090 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2011 | 49 | 0.090 |
Why?
| | Bed Occupancy | 1 | 2011 | 16 | 0.090 |
Why?
| | Research | 1 | 2014 | 448 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2011 | 328 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2012 | 165 | 0.090 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2011 | 150 | 0.090 |
Why?
| | Protein Binding | 1 | 2017 | 2216 | 0.090 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 2010 | 9 | 0.080 |
Why?
| | Structure-Activity Relationship | 2 | 2014 | 570 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2231 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2012 | 233 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2014 | 539 | 0.080 |
Why?
| | Intubation, Intratracheal | 1 | 2012 | 257 | 0.080 |
Why?
| | Cell Lineage | 1 | 2011 | 347 | 0.080 |
Why?
| | Child, Hospitalized | 1 | 2010 | 49 | 0.080 |
Why?
| | Injury Severity Score | 1 | 2011 | 521 | 0.080 |
Why?
| | Analgesics | 1 | 2011 | 206 | 0.080 |
Why?
| | Patient Safety | 1 | 2013 | 308 | 0.080 |
Why?
| | Needs Assessment | 1 | 2011 | 372 | 0.080 |
Why?
| | Cooperative Behavior | 1 | 2012 | 445 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 822 | 0.080 |
Why?
| | RNA, Small Interfering | 3 | 2018 | 622 | 0.080 |
Why?
| | Workflow | 1 | 2010 | 165 | 0.070 |
Why?
| | Overweight | 1 | 2013 | 557 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 518 | 0.070 |
Why?
| | Pilot Projects | 1 | 2013 | 1693 | 0.070 |
Why?
| | Computational Biology | 3 | 2019 | 643 | 0.070 |
Why?
| | Pulmonary Fibrosis | 1 | 2012 | 399 | 0.070 |
Why?
| | Intensive Care Units | 1 | 2013 | 800 | 0.070 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2605 | 0.070 |
Why?
| | Anti-Asthmatic Agents | 1 | 2011 | 393 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1507 | 0.070 |
Why?
| | Internet | 1 | 2012 | 647 | 0.070 |
Why?
| | Inpatients | 1 | 2011 | 496 | 0.060 |
Why?
| | Stereoisomerism | 1 | 2006 | 96 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2013 | 590 | 0.060 |
Why?
| | Microwaves | 1 | 2006 | 37 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1235 | 0.060 |
Why?
| | Down-Regulation | 2 | 2021 | 656 | 0.060 |
Why?
| | Mutation | 3 | 2022 | 3947 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1094 | 0.060 |
Why?
| | Ambulatory Care Information Systems | 1 | 2005 | 5 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1455 | 0.060 |
Why?
| | Ontario | 1 | 2025 | 157 | 0.060 |
Why?
| | Indiana | 1 | 2024 | 33 | 0.060 |
Why?
| | Molecular Structure | 1 | 2006 | 489 | 0.060 |
Why?
| | Aqueous Humor | 2 | 1983 | 34 | 0.060 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 293 | 0.060 |
Why?
| | Patient Readmission | 1 | 2010 | 694 | 0.060 |
Why?
| | Hepatocyte Growth Factor | 1 | 2024 | 35 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 739 | 0.050 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2023 | 6 | 0.050 |
Why?
| | HEK293 Cells | 2 | 2018 | 729 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2024 | 123 | 0.050 |
Why?
| | Ribosomal Proteins | 1 | 2024 | 93 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2010 | 649 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2024 | 82 | 0.050 |
Why?
| | Mice, Nude | 2 | 2015 | 696 | 0.050 |
Why?
| | Hospitals, General | 1 | 2022 | 22 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 102 | 0.050 |
Why?
| | Trabecular Meshwork | 1 | 1983 | 79 | 0.050 |
Why?
| | Receptors, Androgen | 1 | 2024 | 150 | 0.050 |
Why?
| | Exercise | 1 | 2014 | 2044 | 0.050 |
Why?
| | Prevalence | 2 | 2019 | 2710 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1664 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2010 | 978 | 0.050 |
Why?
| | Health Insurance Portability and Accountability Act | 1 | 2022 | 13 | 0.050 |
Why?
| | Middle Aged | 5 | 2025 | 33239 | 0.050 |
Why?
| | Bronchial Diseases | 1 | 2002 | 37 | 0.050 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2002 | 47 | 0.050 |
Why?
| | Immune Evasion | 1 | 2022 | 58 | 0.050 |
Why?
| | Glutathione | 1 | 1983 | 356 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2006 | 593 | 0.050 |
Why?
| | Hepatitis B | 1 | 2022 | 70 | 0.050 |
Why?
| | Appointments and Schedules | 1 | 2002 | 89 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 123 | 0.040 |
Why?
| | Fitness Trackers | 1 | 2021 | 12 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1936 | 0.040 |
Why?
| | Collagen | 1 | 2023 | 446 | 0.040 |
Why?
| | Fibrosis | 1 | 2023 | 552 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2016 | 1249 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2002 | 267 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 24 | 0.040 |
Why?
| | Piperidines | 1 | 2002 | 206 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2020 | 168 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 305 | 0.040 |
Why?
| | 3' Untranslated Regions | 1 | 2020 | 145 | 0.040 |
Why?
| | Prospective Studies | 3 | 2020 | 7573 | 0.040 |
Why?
| | Probability | 1 | 2020 | 304 | 0.040 |
Why?
| | Receptors, Antigen | 1 | 2019 | 16 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 953 | 0.040 |
Why?
| | Demography | 1 | 2020 | 291 | 0.040 |
Why?
| | Bias | 1 | 2020 | 218 | 0.040 |
Why?
| | Missouri | 1 | 1998 | 61 | 0.040 |
Why?
| | Gene Expression | 2 | 2016 | 1500 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 5704 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 790 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2002 | 275 | 0.040 |
Why?
| | Consumer Product Safety | 1 | 2018 | 33 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5744 | 0.040 |
Why?
| | Computer Systems | 1 | 2018 | 45 | 0.040 |
Why?
| | Linear Models | 1 | 2019 | 846 | 0.030 |
Why?
| | Prognosis | 2 | 2020 | 4013 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 393 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2016 | 3009 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2014 | 1269 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 1998 | 169 | 0.030 |
Why?
| | Aquaporin 5 | 1 | 2016 | 3 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2019 | 664 | 0.030 |
Why?
| | Wnt-5a Protein | 1 | 2016 | 23 | 0.030 |
Why?
| | Electric Impedance | 1 | 2016 | 107 | 0.030 |
Why?
| | Students | 1 | 2021 | 624 | 0.030 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2015 | 21 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1180 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2022 | 0.030 |
Why?
| | Alveolar Epithelial Cells | 1 | 2016 | 114 | 0.030 |
Why?
| | Ubiquitination | 1 | 2015 | 102 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2015 | 194 | 0.030 |
Why?
| | SOXB1 Transcription Factors | 1 | 2015 | 61 | 0.030 |
Why?
| | Health Planning Guidelines | 1 | 2014 | 25 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 718 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2014 | 90 | 0.030 |
Why?
| | Drug Synergism | 1 | 2015 | 383 | 0.030 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 167 | 0.030 |
Why?
| | Calibration | 1 | 2014 | 146 | 0.030 |
Why?
| | Proteinuria | 1 | 2014 | 97 | 0.030 |
Why?
| | Drug Design | 1 | 2015 | 167 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2015 | 324 | 0.030 |
Why?
| | Semantics | 1 | 2014 | 92 | 0.030 |
Why?
| | Albumins | 1 | 2014 | 113 | 0.030 |
Why?
| | Podocytes | 1 | 2014 | 63 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2014 | 117 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1616 | 0.030 |
Why?
| | ras Proteins | 1 | 2014 | 153 | 0.030 |
Why?
| | RNA Interference | 1 | 2015 | 466 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 465 | 0.030 |
Why?
| | Drug Discovery | 1 | 2014 | 141 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2797 | 0.030 |
Why?
| | Names | 1 | 2013 | 14 | 0.030 |
Why?
| | Carcinoma | 1 | 2015 | 238 | 0.030 |
Why?
| | Systems Integration | 1 | 2013 | 37 | 0.030 |
Why?
| | Aged | 2 | 2025 | 23808 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2014 | 5106 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 327 | 0.020 |
Why?
| | Quality Control | 1 | 2013 | 171 | 0.020 |
Why?
| | Research Personnel | 1 | 2014 | 171 | 0.020 |
Why?
| | Airway Extubation | 1 | 2013 | 57 | 0.020 |
Why?
| | Creatinine | 1 | 2014 | 499 | 0.020 |
Why?
| | Ligands | 1 | 2014 | 661 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2012 | 43 | 0.020 |
Why?
| | Medical Errors | 1 | 2013 | 112 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1758 | 0.020 |
Why?
| | Gene Targeting | 1 | 2011 | 81 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2014 | 695 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1301 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2831 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2878 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2011 | 133 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1993 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2011 | 148 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 504 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2829 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 951 | 0.020 |
Why?
| | Zebrafish | 1 | 2014 | 495 | 0.020 |
Why?
| | Actins | 1 | 2012 | 416 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2011 | 600 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2013 | 642 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1231 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2011 | 427 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5639 | 0.020 |
Why?
| | Kidney | 1 | 2014 | 1467 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1684 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2020 | 10748 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 1572 | 0.010 |
Why?
| | Information Centers | 1 | 2005 | 4 | 0.010 |
Why?
| | Hospitals | 1 | 2010 | 684 | 0.010 |
Why?
| | Databases as Topic | 1 | 2005 | 67 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2375 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1301 | 0.010 |
Why?
| | Diamide | 1 | 1983 | 5 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4282 | 0.010 |
Why?
| | Iodoacetates | 1 | 1983 | 3 | 0.010 |
Why?
| | Iodoacetamide | 1 | 1983 | 5 | 0.010 |
Why?
| | Ethylmaleimide | 1 | 1983 | 18 | 0.010 |
Why?
| | Carmustine | 1 | 1983 | 50 | 0.010 |
Why?
| | Sulfhydryl Reagents | 1 | 1983 | 12 | 0.010 |
Why?
| | Anterior Chamber | 1 | 1983 | 22 | 0.010 |
Why?
| | Free Radicals | 1 | 1983 | 110 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4145 | 0.010 |
Why?
| | Tryptases | 1 | 2002 | 13 | 0.010 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 39 | 0.010 |
Why?
| | Rabbits | 1 | 1983 | 792 | 0.010 |
Why?
| | Pulmonary Eosinophilia | 1 | 2002 | 27 | 0.010 |
Why?
| | Lens, Crystalline | 1 | 1983 | 125 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 1983 | 327 | 0.010 |
Why?
| | Time | 1 | 2002 | 82 | 0.010 |
Why?
| | Ovalbumin | 1 | 2002 | 183 | 0.010 |
Why?
| | Pulmonary Edema | 1 | 2002 | 107 | 0.010 |
Why?
| | Mucus | 1 | 2002 | 79 | 0.010 |
Why?
| | Bronchial Hyperreactivity | 1 | 2002 | 111 | 0.010 |
Why?
| | Cattle | 1 | 1983 | 981 | 0.010 |
Why?
| | Amino Acids | 1 | 1983 | 497 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1983 | 1059 | 0.010 |
Why?
| | Eosinophils | 1 | 2002 | 332 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2002 | 655 | 0.010 |
Why?
| | Glucose | 1 | 1983 | 1019 | 0.010 |
Why?
| | Risk Factors | 1 | 2012 | 10332 | 0.010 |
Why?
| | Decision Support Techniques | 1 | 2002 | 418 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1570 | 0.010 |
Why?
| | Cytokines | 1 | 2002 | 2084 | 0.010 |
Why?
| | Inflammation | 1 | 2002 | 2835 | 0.010 |
Why?
| | Lung | 1 | 2002 | 4063 | 0.000 |
Why?
|
|
Kahn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|